A Comprehensive Monograph on Piperacillin (DB00319): Pharmacology, Clinical Utility, and Safety Profile

Drug Identity and Physicochemical Properties

Introduction

Piperacillin is a semi-synthetic, fourth-generation, extended-spectrum ureidopenicillin antibiotic derived from ampicillin.[1] As a member of the β-lactam class of antimicrobials, it occupies a central role in the management of complex bacterial infections, particularly those encountered in the hospital setting. Its chemical structure, which incorporates a polar side chain, enhances its penetration into Gram-negative bacteria and confers a degree of stability against cleavage by certain Gram-negative β-lactamase enzymes.[4] This structural feature is responsible for its potent activity against the opportunistic pathogen

Pseudomonas aeruginosa, earning it the designation of an "anti-pseudomonal penicillin".[4]

In contemporary clinical practice, piperacillin is almost exclusively formulated and administered in a fixed-dose combination with tazobactam, a β-lactamase inhibitor.[4] The rationale for this combination is rooted in the global challenge of antimicrobial resistance. Many clinically significant bacteria have acquired the ability to produce β-lactamase enzymes, which hydrolyze and inactivate penicillin antibiotics, rendering them ineffective. Tazobactam serves as a "protector" molecule; it irreversibly binds to and inhibits many of these bacterial enzymes, thereby restoring and extending piperacillin's spectrum of activity.[7] This combination product, piperacillin/tazobactam, is a cornerstone of empiric therapy for serious, moderate-to-severe, and often polymicrobial infections, including intra-abdominal infections, hospital-acquired pneumonia, and febrile neutropenia.[4]

Chemical and Physical Data

The precise identification and characterization of a pharmaceutical agent's physicochemical properties are fundamental to understanding its formulation, stability, and behavior in vivo. Piperacillin exists in several forms, including its anhydrous base, a monohydrate, and its clinically utilized sodium salt, each with distinct identifiers and properties. This distinction is critical for both pharmaceutical science and clinical application. For instance, the limited aqueous solubility of the piperacillin base necessitates its formulation as a highly soluble sodium salt for intravenous administration.[2] The detailed properties of piperacillin are summarized in Table 1.1.

Table 1.1: Drug Identification and Physicochemical Properties of Piperacillin

Property	Value	Source(s)
DrugBank ID	DB00319	1
Drug Type	Small Molecule	1
CAS Numbers	66258-76-2 (Monohydrate)	2
	61477-96-1 (Anhydrous)	14
	59703-84-3 (Sodium Salt)	11
Chemical Formula	C23​H27​N5​O7​S (Anhydrous)	1
	C23​H27​N5​O7​S⋅H2​O (Monohydrate)	2
Molecular Weight	517.56 g/mol (Anhydrous)	1
	535.57 g/mol (Monohydrate)	2
	539.54 g/mol (Sodium Salt)	8
IUPAC Name	(2S,5R,6R)-6-{amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid	1
Synonyms	Pipracil, Pipercillin, Pipril, Piperacillina, Pipéracilline, Piperacillinum	1
Physical Appearance	White to off-white crystalline powder	2
Solubility	Anhydrous/Hydrate: Sparingly soluble in water (0.119 g/L); freely soluble in methanol.	2
	Sodium Salt: Soluble in water, methanol, and ethanol.	11
Storage Conditions	Store at 2-8 °C; protect from light.	2
pKa (Predicted)	2.44 ± 0.50	12
LogP	0.3 - 0.5	3

Clinical Pharmacology

Mechanism of Action

Piperacillin exerts its bactericidal effect through a well-characterized mechanism common to all β-lactam antibiotics: the inhibition of bacterial cell wall synthesis.[9] The structural integrity of the bacterial cell is maintained by a rigid outer layer of peptidoglycan, a complex polymer of sugars and amino acids. The final and critical step in the synthesis of this layer is the cross-linking of adjacent peptidoglycan strands, a reaction catalyzed by a family of bacterial enzymes known as penicillin-binding proteins (PBPs).[2]

Piperacillin's molecular structure mimics the D-Ala-D-Ala terminal of the natural peptide substrates of these enzymes.[4] This structural similarity allows piperacillin to bind with high affinity to the active site of PBPs, specifically forming a stable, covalent acyl-enzyme complex with a key serine residue.[4] This binding is effectively irreversible and inactivates the PBP, thereby preventing the essential transpeptidation (cross-linking) reaction.[2] The inhibition of cell wall biosynthesis results in the formation of a structurally deficient and weakened cell envelope. In the hypotonic environment of host tissues, the compromised cell wall is unable to withstand the high internal osmotic pressure, leading to cell swelling, lysis, and ultimately, bacterial death.[2] This bactericidal action is most pronounced in actively replicating bacteria that are continuously synthesizing new peptidoglycan.[21] Evidence also suggests that piperacillin may interfere with an autolysin inhibitor, leading to the unopposed action of bacterial autolytic enzymes that further contribute to the degradation of the cell wall.[1] In pathogens such as

Streptococcus pneumoniae, piperacillin has been shown to bind to specific targets including serine-type D-Ala-D-Ala carboxypeptidase, PBP 2a, and PBP 2B.[1]

Rationale for Combination with Tazobactam

The clinical utility of piperacillin as a standalone agent is severely limited by the pervasive mechanism of bacterial resistance mediated by β-lactamase enzymes. These enzymes, produced by a wide range of bacteria, hydrolyze the amide bond in the four-membered β-lactam ring that is characteristic of all penicillin antibiotics, rendering the drug molecule inactive.[2] To overcome this resistance, piperacillin is combined with tazobactam.

Tazobactam is a derivative of the penicillin nucleus (a penicillanic acid sulfone) that possesses minimal intrinsic antibacterial activity but functions as a potent, mechanism-based, irreversible inhibitor of many clinically important β-lactamases.[8] It effectively neutralizes a broad range of enzymes, including the Richmond-Sykes class III and Bush class 2b and 2b' enzymes, which encompass many common plasmid- and chromosomally-mediated β-lactamases found in pathogens like

Staphylococcus aureus, Haemophilus influenzae, Escherichia coli, and Bacteroides fragilis.[8] The mechanism of inhibition involves tazobactam acting as a "suicide substrate." It binds to the active site of the β-lactamase, forming a stable acyl-enzyme intermediate that prevents the enzyme from binding to and hydrolyzing piperacillin.[4] By sacrificing itself, tazobactam protects piperacillin from degradation, thereby restoring its activity against many β-lactamase-producing organisms that would otherwise be resistant.[6]

However, this protective effect is not absolute. The combination of piperacillin and tazobactam is not a universal solution to β-lactam resistance. A crucial limitation is that tazobactam is a poor inhibitor of certain classes of β-lactamases, most notably the AmpC β-lactamases and various carbapenemases.[4] AmpC enzymes are chromosomally encoded in several important Gram-negative pathogens, including

Enterobacter cloacae, Serratia marcescens, and Citrobacter freundii, and can be induced to high levels of expression by exposure to β-lactam antibiotics. The intrinsic resistance of these enzymes to tazobactam means that the combination agent may be ineffective against infections caused by these organisms, even if susceptibility testing suggests otherwise under certain conditions. This has profound clinical implications. Empiric use of piperacillin/tazobactam for a serious infection caused by an AmpC-producing organism can lead to the selection of resistant subpopulations and subsequent treatment failure. This underscores the importance of understanding local resistance patterns, utilizing rapid diagnostic tests when available, and selecting alternative agents, such as carbapenems or cefepime, when AmpC-producing pathogens are suspected or confirmed.

Pharmacodynamics (PD)

The bactericidal activity of piperacillin, like other β-lactam antibiotics, is characterized by a time-dependent killing mechanism.[4] This means that the primary determinant of its clinical efficacy is not the peak concentration achieved, but rather the duration of time that the drug concentration remains above a critical threshold. The key pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with bacteriological success for piperacillin is the percentage of the dosing interval during which the concentration of the free, unbound drug exceeds the minimum inhibitory concentration (MIC) of the target pathogen (%fT>MIC).[4]

For maximal bactericidal effect against Gram-negative bacteria, including P. aeruginosa, the target %fT>MIC is generally considered to be 60–70% of the dosing interval. For Gram-positive bacteria, a slightly lower target of 40–50% is often sufficient.[4] Studies have shown that once drug concentrations exceed the MIC by a factor of four to six, there is minimal additional increase in the rate of bacterial killing; this concentration-independent effect further emphasizes the paramount importance of maintaining exposure duration over achieving high peak concentrations.[4]

This fundamental pharmacodynamic principle has directly driven an evolution in the clinical administration of piperacillin/tazobactam. The drug possesses a relatively short elimination half-life of approximately 0.7 to 1.2 hours in individuals with normal renal function.[4] When administered via a traditional short-duration intravenous infusion (e.g., 30 minutes), plasma concentrations peak rapidly but also decline quickly, potentially falling below the MIC for a substantial portion of the dosing interval.[26] While this may be adequate for highly susceptible organisms with very low MICs, it can result in suboptimal target attainment for less susceptible pathogens, such as

P. aeruginosa or certain Enterobacterales. To address this, clinical practice has increasingly adopted the strategy of extended-infusion (EI) administration. By infusing the same total dose over a longer period (e.g., 3 to 4 hours instead of 30 minutes), the peak plasma concentration is lower, but the drug concentration is maintained above the MIC for a significantly longer duration within the dosing interval.[27] This method directly optimizes the %fT>MIC, enhancing the probability of achieving the pharmacodynamic target and improving clinical outcomes, particularly in critically ill patients and for infections caused by organisms with elevated MICs.[4]

Pharmacokinetics (PK)

A thorough understanding of the absorption, distribution, metabolism, and excretion (ADME) of piperacillin is essential for designing safe and effective dosing regimens.

• Absorption: Piperacillin is not absorbed from the gastrointestinal tract and therefore must be administered parenterally. Following intravenous infusion, peak plasma concentrations are achieved immediately upon completion of the infusion.[4]
• Distribution: Piperacillin is widely distributed throughout the body. It penetrates well into various tissues and body fluids, including the intestinal mucosa, gallbladder, lung, bile, and female reproductive organs (uterus, ovary, fallopian tube).[8] In these tissues, mean concentrations typically reach 50% to 100% of the corresponding plasma concentrations.[22] The volume of distribution (Vd) is approximately 15 to 22 liters, consistent with distribution primarily into the extracellular fluid.[4] Plasma protein binding is low for both piperacillin (approximately 30%) and tazobactam (approximately 23-30%), meaning a large fraction of the drug in circulation is free and microbiologically active. The binding of one component is not affected by the presence of the other.[8]
• Metabolism: Piperacillin undergoes minimal biotransformation in humans. A small fraction is metabolized to a desethyl metabolite, which retains minor microbiological activity.[4] Tazobactam is metabolized to a greater extent (approximately 20% of a dose) to a single metabolite that is pharmacologically and microbiologically inactive.[8]
• Excretion: Both piperacillin and tazobactam are primarily and rapidly eliminated from the body by the kidneys via a combination of glomerular filtration and active tubular secretion.[8] Approximately 68-69% of an administered dose of piperacillin is recovered in the urine as unchanged, active drug.[8] The elimination half-life in healthy adults is short, typically ranging from 0.7 to 1.2 hours.[4] This short half-life necessitates frequent dosing or extended infusions to maintain therapeutic concentrations.

Table 2.1: Key Pharmacokinetic Parameters of Piperacillin/Tazobactam in Adults with Normal Renal Function

Parameter	Value	Source(s)
Elimination Half-life (t1/2​)	0.7 - 1.2 hours	8
Plasma Protein Binding	~30% (Piperacillin)	8
	~23-30% (Tazobactam)	8
Volume of Distribution (Vd​)	~15 - 22 L	4
Total Body Clearance	~13.7 - 16.0 L/h	31
Primary Route of Elimination	Renal (Glomerular filtration and tubular secretion)	8
Metabolism	Minimal (<20% for Piperacillin); ~20% for Tazobactam	8

Antimicrobial Spectrum and Mechanisms of Resistance

Spectrum of Activity

The combination of piperacillin with tazobactam results in an exceptionally broad spectrum of antimicrobial activity that is a defining feature of its clinical utility. It is active against a wide array of Gram-positive, Gram-negative, and anaerobic pathogens, making it a valuable agent for the empiric treatment of polymicrobial infections.[2]

• Gram-Positive Aerobes: The spectrum includes activity against methicillin-susceptible Staphylococcus aureus (MSSA), coagulase-negative staphylococci, Streptococcus pneumoniae, viridans group streptococci, Streptococcus pyogenes, and Enterococcus faecalis. It is not active against methicillin-resistant Staphylococcus aureus (MRSA) or most strains of Enterococcus faecium.[9]
• Gram-Negative Aerobes: Piperacillin/tazobactam is highly active against many clinically important Gram-negative organisms. This includes β-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis. It also covers a wide range of Enterobacterales, such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Serratia marcescens. A key feature is its reliable activity against Pseudomonas aeruginosa.[2]
• Anaerobes: The combination provides excellent coverage of many anaerobic bacteria, including the Bacteroides fragilis group (B. fragilis, B. ovatus, B. thetaiotaomicron, B. vulgatus), which are common pathogens in intra-abdominal infections.[2]

The potency of piperacillin, and the synergistic effect of tazobactam, can be quantified by examining the MICs for various pathogens. The MIC is the lowest concentration of an antimicrobial that prevents visible growth of a microorganism after overnight incubation.

Table 3.1: Representative Minimum Inhibitory Concentration (MIC) Values for Key Pathogens

Organism	Agent	MIC Range (µg/mL)	Source(s)
Neisseria spp.	Piperacillin	0.015 – 32	2
Bacteroides fragilis	Piperacillin	0.25 – 32	2
ESBL-producing E. coli	Piperacillin alone	>128	37
ESBL-producing E. coli	Piperacillin/Tazobactam (4 µg/mL)	2	37

A significant area of clinical investigation and debate is the role of piperacillin/tazobactam in treating infections caused by Enterobacterales that produce extended-spectrum β-lactamases (ESBLs). Historically, carbapenems were considered the treatment of choice for any serious infection involving these organisms.[38] However, the escalating prevalence of carbapenem-resistant organisms has intensified the search for effective "carbapenem-sparing" regimens. Piperacillin/tazobactam is a leading candidate, but its efficacy is a subject of nuanced discussion.[25]

The evidence base is complex and appears to be dependent on the site of infection and severity of illness. For instance, several observational studies and a randomized controlled trial have shown that piperacillin/tazobactam can be an effective treatment for urinary tract infections caused by ESBL-producing E. coli, particularly when the MIC is within the susceptible range (e.g., ≤16 µg/mL).[38] In contrast, for more severe infections like bacteremia, the evidence is less favorable. The landmark MERINO randomized controlled trial demonstrated that patients with bloodstream infections caused by ceftriaxone-resistant

E. coli or K. pneumoniae had significantly higher all-cause mortality at 30 days when treated with piperacillin/tazobactam compared to meropenem.[38] This suggests that while piperacillin/tazobactam may be a viable option for less severe, non-bacteremic infections like cystitis, carbapenems remain the preferred agent for serious, life-threatening infections caused by ESBL-producing organisms. The decision to use piperacillin/tazobactam for an ESBL infection must therefore be made cautiously, taking into account the specific pathogen, its MIC, the source of the infection, and the clinical stability of the patient.

Mechanisms of Bacterial Resistance

Despite the protective effect of tazobactam, bacteria have evolved several mechanisms to overcome the activity of piperacillin/tazobactam.

• Enzymatic Degradation: The most prevalent mechanism of resistance is the production of β-lactamase enzymes that are not effectively inhibited by tazobactam. As previously discussed, this includes the chromosomally-inducible AmpC β-lactamases. Additionally, the emergence and spread of various carbapenemases (e.g., Klebsiella pneumoniae carbapenemase [KPC], OXA-type carbapenemases) confer high-level resistance to piperacillin/tazobactam as these enzymes readily hydrolyze piperacillin and are not inhibited by tazobactam.[4]
• Target Site Modification: Resistance can arise from alterations in the structure of the PBPs, the molecular targets of piperacillin. Mutations in the genes encoding these proteins can decrease the binding affinity of the antibiotic, rendering it less effective at inhibiting cell wall synthesis. This is the primary mechanism of resistance in MRSA, which acquires the mecA gene encoding for a low-affinity PBP2a. A similar mechanism involving low-affinity PBPs contributes to resistance in Enterococcus faecium (PBP5) and certain strains of penicillin-resistant Streptococcus pneumoniae (e.g., altered PBP2b).[4]
• Reduced Permeability and Efflux: Gram-negative bacteria possess an outer membrane that acts as a selective barrier. Decreased expression of outer membrane porin proteins can limit the influx of piperacillin into the periplasmic space where the PBPs are located. Concurrently, bacteria can upregulate the expression of multidrug efflux pumps that actively transport the antibiotic out of the cell before it can reach its target. These mechanisms are particularly important in conferring resistance in non-fermenting Gram-negative bacilli like P. aeruginosa and can also contribute to resistance in K. pneumoniae.[4]

Clinical Efficacy and Therapeutic Applications

Approved Clinical Indications (FDA & EMA)

Piperacillin/tazobactam is a globally utilized antibiotic, with approved indications that may vary slightly between major regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These differences often reflect the specific clinical trial data submitted to each agency and the focus of their respective regulatory reviews.

U.S. Food and Drug Administration (FDA) Approved Indications:

The combination product, marketed as Zosyn®, is approved in the United States for the treatment of the following infections in adults and, where specified, pediatric patients 39:

• Intra-abdominal Infections: For appendicitis (complicated by rupture or abscess) and peritonitis in adults and pediatric patients 2 months of age and older.
• Nosocomial Pneumonia (Hospital-Acquired Pneumonia): For moderate to severe nosocomial pneumonia in adults and pediatric patients 2 months of age and older.
• Skin and Skin Structure Infections: For uncomplicated and complicated infections in adults, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections.
• Female Pelvic Infections: For postpartum endometritis or pelvic inflammatory disease (PID) in adults.
• Community-Acquired Pneumonia: For moderate-severity community-acquired pneumonia in adults.

European Medicines Agency (EMA) Approved Indications:

In the European Union, the combination product, marketed as Tazocin® and other trade names, underwent a harmonisation procedure to standardize its indications across member states. The approved indications for adults and adolescents include 30:

• Severe Pneumonia: Including hospital-acquired and ventilator-associated pneumonia.
• Complicated Urinary Tract Infections: Including pyelonephritis.
• Complicated Intra-abdominal Infections.
• Complicated Skin and Soft Tissue Infections: Including diabetic foot infections.
• Bacteremia: When it is associated with, or suspected to be associated with, any of the infections listed above.
• Febrile Neutropenia: For the management of patients with fever suspected to be due to a bacterial infection.

For pediatric patients aged 2 to 12 years, the EMA-approved indications are complicated intra-abdominal infections and the management of febrile neutropenia.[42]

The divergence between these regulatory approvals highlights important nuances. The EMA's explicit approval for complicated UTIs and febrile neutropenia reflects a formal recognition of the drug's extensive use and evidence base in these common and serious clinical scenarios. The FDA label, while not precluding such uses, structures its indications around specific infection types proven in the registration trials. This demonstrates how regulatory labels can differ globally and emphasizes the need for clinicians to be familiar with the approved indications within their specific jurisdiction.

Off-Label and Investigational Uses

Given its broad spectrum of activity, piperacillin/tazobactam is frequently used in clinical practice for infections that may not be explicitly listed on all regulatory labels. These off-label uses are often supported by clinical guidelines and extensive clinical experience. Such applications include the treatment of septicemia, bone and joint infections (osteomyelitis), and other complex polymicrobial infections where broad coverage is desired for initial empiric therapy.[29] While piperacillin demonstrates good penetration into the central nervous system during inflammation, its use for meningitis is approached with caution, as the penetration of tazobactam may be insufficient to protect piperacillin from β-lactamase-producing pathogens within the cerebrospinal fluid.[31]

Synopsis of Clinical Trial Evidence

The efficacy of piperacillin/tazobactam is supported by a large body of evidence from numerous multicenter, randomized, double-blind clinical trials that have established its non-inferiority or superiority to various comparator agents.[10]

• In studies of patients with intra-abdominal infections, piperacillin/tazobactam demonstrated significantly higher clinical and bacteriological response rates compared to a specific regimen of imipenem/cilastatin.[6]
• For the treatment of community-acquired pneumonia, clinical trials showed that piperacillin/tazobactam was significantly more effective than the combination of ticarcillin/clavulanic acid.[6]
• In the management of severe infections like ventilator-associated pneumonia and febrile neutropenia, a regimen of piperacillin/tazobactam combined with an aminoglycoside (amikacin) was found to be at least as effective as a standard regimen of ceftazidime plus amikacin.[6]
• The drug continues to be studied in post-marketing (Phase 4) trials to further define its pharmacokinetics and optimize dosing in specific, complex patient populations, such as those undergoing continuous renal replacement therapy (CRRT).[46]

Safety, Tolerability, and Risk Management

Adverse Drug Reactions (ADRs)

Piperacillin/tazobactam is generally well-tolerated, but is associated with a range of adverse drug reactions, from common and mild to rare and life-threatening. The safety profile has been extensively characterized through decades of clinical trials and post-marketing surveillance.[30] A systematic summary of adverse reactions is presented in Table 5.1.

Table 5.1: Summary of Adverse Reactions to Piperacillin/Tazobactam by System Organ Class and Frequency

System Organ Class	Very Common (≥1/10)	Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to <1/100)	Rare (≥1/10,000 to <1/1000)	Frequency Not Known
Infections and Infestations		Candidiasis (oral, vaginal)		Clostridioides difficile colitis
Blood and Lymphatic System		Thrombocytopenia, Anemia, Eosinophilia	Leukopenia	Agranulocytosis	Pancytopenia, Neutropenia, Hemolytic anemia, Thrombocytosis
Immune System					Anaphylactic/Anaphylactoid reactions (including shock), Hypersensitivity
Metabolism and Nutrition			Hypokalemia, Hypoglycemia
Psychiatric		Insomnia			Delirium
Nervous System		Headache	Seizures
Vascular			Hypotension, Thrombophlebitis, Phlebitis, Flushing
Respiratory, Thoracic				Epistaxis	Eosinophilic pneumonia
Gastrointestinal	Diarrhea	Nausea, Vomiting, Constipation, Abdominal pain, Dyspepsia		Stomatitis
Hepatobiliary		Alanine aminotransferase (ALT) increased, Aspartate aminotransferase (AST) increased	Blood bilirubin increased		Hepatitis, Jaundice
Skin and Subcutaneous Tissue		Rash (including maculopapular), Pruritus	Erythema multiforme, Urticaria	Toxic Epidermal Necrolysis (TEN)	Stevens-Johnson Syndrome (SJS), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Acute Generalized Exanthematous Pustulosis (AGEP)
Renal and Urinary		Blood creatinine increased, Blood urea nitrogen increased			Renal failure, Tubulointerstitial nephritis
General Disorders		Pyrexia, Injection site reaction	Chills
Investigations		Coombs direct test positive, Activated partial thromboplastin time prolonged	Prothrombin time prolonged		Bleeding time prolonged

Source: Synthesized from [30]

Contraindications, Warnings, and Precautions

Safe use of piperacillin/tazobactam requires careful patient selection and vigilant monitoring for potentially severe toxicities.

• Contraindications: The use of piperacillin/tazobactam is absolutely contraindicated in patients with a history of severe hypersensitivity reactions, such as anaphylaxis, to any β-lactam antibiotic, including penicillins, cephalosporins, carbapenems, or monobactams, or to β-lactamase inhibitors.[36]
• Warnings and Precautions:
• Hypersensitivity Reactions: Serious and occasionally fatal anaphylactic/anaphylactoid reactions have been reported. These are more likely in individuals with a history of sensitivity to multiple allergens. Before initiating therapy, careful inquiry regarding previous hypersensitivity reactions is mandatory. If an allergic reaction occurs, the drug must be discontinued immediately and appropriate emergency treatment instituted.[41]
• Severe Cutaneous Adverse Reactions (SCARs): Life-threatening skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP), have been reported. Patients should be monitored closely for the development of skin rashes. If lesions progress, piperacillin/tazobactam must be discontinued promptly.[39]
• Hemophagocytic Lymphohistiocytosis (HLH): This is a rare but life-threatening syndrome of pathologic immune activation that has been reported in patients treated with piperacillin/tazobactam, often after more than 10 days of therapy. Clinicians should be alert for signs and symptoms of excessive systemic inflammation, such as persistent fever, rash, hepatosplenomegaly, and cytopenias. If HLH is suspected, the drug should be discontinued immediately.[30]
• Hematologic Effects: Bleeding manifestations can occur, sometimes associated with abnormalities in coagulation tests (e.g., clotting time, prothrombin time, platelet aggregation). These events are more likely in patients with renal failure. Leukopenia and neutropenia may also occur, particularly with prolonged therapy (e.g., >21 days). Periodic assessment of hematopoietic function and coagulation parameters is recommended during extended courses of treatment.[30]
• Central Nervous System Effects: Neuromuscular excitability or convulsions (seizures) can occur, especially when high doses are administered or in patients with impaired renal function. This is a direct consequence of drug accumulation.[30]
• Clostridioides difficile-Associated Diarrhea (CDAD): As with nearly all broad-spectrum antibacterial agents, treatment with piperacillin/tazobactam alters the normal colonic flora, which can lead to the overgrowth of C. difficile. This can result in a spectrum of illness from mild diarrhea to life-threatening pseudomembranous colitis. CDAD should be considered in any patient who presents with diarrhea following antibiotic use, even up to two months after cessation of therapy.[48]

A critical aspect of the safety profile of piperacillin is the central role of renal function. The drug is predominantly cleared by the kidneys, and any degree of renal impairment leads to decreased clearance and subsequent drug accumulation.[8] This accumulation is not a benign phenomenon; it is causally linked to an increased risk of several of the most severe toxicities. The elevated and prolonged drug concentrations seen in patients with renal insufficiency directly increase the risk of neurotoxicity (seizures) and bleeding diatheses.[30] Furthermore, piperacillin/tazobactam itself has been identified as an independent risk factor for nephrotoxicity, particularly in critically ill patients, potentially creating a deleterious cycle of worsening renal function and further drug accumulation.[39] Therefore, the assessment of baseline renal function and diligent monitoring throughout the course of therapy are arguably the most critical safety measures to be undertaken for any patient receiving this medication.

Clinically Significant Drug-Drug Interactions

Piperacillin/tazobactam can participate in several clinically important drug-drug interactions, primarily related to its mechanism of renal excretion and its effects on coagulation.

• Probenecid: Probenecid competes with piperacillin and tazobactam for active tubular secretion in the kidneys. Concomitant administration significantly prolongs the elimination half-lives of piperacillin (by 21%) and tazobactam (by 71%), leading to higher plasma concentrations. This combination is generally not recommended unless the potential benefit of increased exposure is specifically desired and outweighs the risks.[7]
• Vancomycin: Multiple observational studies and clinical reports have suggested that the concurrent administration of piperacillin/tazobactam and vancomycin is associated with an increased incidence of acute kidney injury (AKI) compared to either agent alone or vancomycin with other β-lactams. The precise mechanism is not fully understood. Due to this risk, it is recommended to closely monitor renal function in patients receiving this combination.[39]
• Anticoagulants (e.g., Heparin, Warfarin): Piperacillin can interfere with platelet function and coagulation. When used concomitantly with anticoagulants, there may be an additive effect, increasing the risk of bleeding. More frequent monitoring of coagulation parameters (e.g., PT, aPTT) is warranted.[7]
• Methotrexate: Penicillins can reduce the renal clearance of methotrexate by competing for renal tubular secretion. This can lead to elevated and prolonged serum concentrations of methotrexate, increasing the risk of hematologic and gastrointestinal toxicity. Patients receiving this combination require close monitoring for signs of methotrexate toxicity.[7]
• Neuromuscular Blockers (e.g., Vecuronium): Piperacillin has been shown to prolong the duration of neuromuscular blockade induced by vecuronium and other non-depolarizing muscle relaxants. Patients undergoing surgery or mechanical ventilation should be monitored for prolonged neuromuscular blockade if receiving concurrent therapy.[7]
• Aminoglycosides: There is a physicochemical incompatibility between piperacillin and aminoglycosides. If mixed together in the same intravenous solution or administered through the same IV line without adequate flushing, piperacillin can form a complex with and inactivate the aminoglycoside.[30] They must be administered separately. In patients on hemodialysis, piperacillin administration can also lead to a significant reduction in the serum concentrations of tobramycin, necessitating therapeutic drug monitoring.[39]

Overdose and Toxicity Management

Overdose with piperacillin/tazobactam is rare but can occur, particularly in patients with severe renal impairment who do not receive appropriate dose adjustments. Manifestations of overdose are extensions of the adverse effect profile and may include nausea, vomiting, and diarrhea. More serious signs of significant overdose include neuromuscular hyperexcitability, myoclonus, or convulsions (seizures).[23]

There is no specific antidote for piperacillin/tazobactam overdose. Management is entirely supportive and symptomatic.[23] In cases of severe overdose, particularly when associated with renal failure and significant neurotoxicity, hemodialysis can be an effective intervention. Hemodialysis can remove 30% to 50% of the piperacillin/tazobactam dose over a four-hour period and should be considered in clinically unstable patients.[23]

Formulations, Dosing, and Administration

Formulations and Commercial Presentations

Piperacillin/tazobactam is supplied for intravenous administration in several forms to accommodate different hospital pharmacy workflows and patient needs.

• Lyophilized Powder: The most common formulation is a sterile, white to off-white lyophilized (cryodesiccated) powder in single-dose or larger pharmacy bulk vials. This powder must be reconstituted with a compatible diluent (e.g., 0.9% Sodium Chloride, Sterile Water for Injection) and then further diluted to the final infusion volume before administration.[22]
• Premixed Frozen Solutions: To improve convenience and reduce preparation time and potential for errors, the drug is also available as a premixed, frozen solution in a dextrose-containing vehicle (e.g., Zosyn® in GALAXY® containers). These containers are thawed at room temperature or under refrigeration prior to use.[29]
• Brand Names: The combination is marketed globally under several brand names. The most prominent are Zosyn® in the United States and Tazocin® in Europe, Canada, and other international markets.[1] Other registered trade names include Tazobac®, Tazocel®, and Tazocilline®.[45]
• Formulation Excipients: A significant development in the product's history was the reformulation of the Zosyn® brand. The original formulation was prone to the formation of particulate matter (identified as insoluble piperacillin dimers) upon reconstitution and storage.[57] To address this stability issue, the formulation was modified to include edetate disodium dihydrate (EDTA) as a chelating agent and sodium citrate as a buffer. This reformulation not only improved the stability and reduced particulate formation but also expanded the compatibility of the drug, allowing for Y-site co-administration with certain aminoglycosides (amikacin and gentamicin) and use with Lactated Ringer's solution.[10] It is important to note that some generic formulations of piperacillin/tazobactam may not contain these excipients and may therefore have different stability and compatibility profiles.[29]

Dosing and Administration Guidelines

Dosing of piperacillin/tazobactam is dependent on the indication, severity of infection, and the patient's renal function.

• Standard Adult Dosing (for most indications): The usual dosage for adults with normal renal function is 3.375 g (3 g piperacillin / 0.375 g tazobactam) administered intravenously every 6 hours.[26]
• Nosocomial Pneumonia Dosing (Adults): For the treatment of nosocomial pneumonia, a higher dose of 4.5 g (4 g piperacillin / 0.5 g tazobactam) IV every 6 hours is recommended, typically in combination with an aminoglycoside for coverage of P. aeruginosa.[26]
• Pediatric Dosing: Dosing in children is weight-based and varies by age.
• 2 to 9 months of age: 80-90 mg/kg of the piperacillin component IV every 6 to 8 hours, depending on the indication.[39]
• Older than 9 months (up to 40 kg): 100-112.5 mg/kg of the piperacillin component IV every 6 to 8 hours, depending on the indication.[39]
• Administration: The standard method of administration is via intravenous infusion over 30 minutes.[26]
• Extended-Infusion Dosing: As discussed in the Pharmacodynamics section, there is a strong rationale for administering the drug via extended infusion to optimize the %fT>MIC. A common extended-infusion regimen is 3.375 g or 4.5 g infused over 3 to 4 hours, administered every 8 hours. This strategy is increasingly preferred, especially in critically ill patients, for infections caused by less susceptible pathogens, or as part of antimicrobial stewardship efforts to maximize efficacy.[27]

Dose Adjustments in Special Populations

Dose adjustment of piperacillin/tazobactam is critically important in patients with renal impairment to prevent drug accumulation and toxicity. Dosing must be modified based on the patient's estimated creatinine clearance (CrCl).

Table 6.1: Recommended Dosage Adjustments for Piperacillin/Tazobactam in Adult Renal Impairment

Creatinine Clearance (CrCl)	All Indications (except Nosocomial Pneumonia)	Nosocomial Pneumonia
> 40 mL/min	3.375 g IV every 6 hours	4.5 g IV every 6 hours
20 - 40 mL/min	2.25 g IV every 6 hours	3.375 g IV every 6 hours
< 20 mL/min	2.25 g IV every 8 hours	2.25 g IV every 6 hours
Hemodialysis (HD)	2.25 g IV every 12 hours, plus 0.75 g after each dialysis session	2.25 g IV every 8 hours, plus 0.75 g after each dialysis session
Continuous Ambulatory Peritoneal Dialysis (CAPD)	2.25 g IV every 12 hours	2.25 g IV every 8 hours

Source: Synthesized from FDA prescribing information.[29] Dosing may vary by institutional protocol. Extended-infusion regimens also require renal adjustment.

Regulatory History and Expert Synthesis

Regulatory Milestones

The development and approval of piperacillin and its combination with tazobactam represent important milestones in the history of antimicrobial therapy.

• 1974: The piperacillin molecule was first patented.[4]
• 1981: Piperacillin was approved for medical use in the United States as a standalone agent, valued for its extended spectrum of activity.[4]
• October 22, 1993: The fixed-dose combination product, piperacillin/tazobactam (Zosyn®), received its initial approval from the U.S. FDA, marking a significant advancement in the ability to treat infections caused by β-lactamase-producing bacteria.[63]
• September 30, 2005: The FDA approved a reformulated version of Zosyn® containing EDTA and sodium citrate. This change was implemented to address quality and stability concerns related to the formation of particulate matter in the original formulation and to improve its compatibility with other intravenous solutions and drugs.[57]
• 2009: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) completed a referral procedure to harmonize the prescribing information, including indications and dosing, for Tazocin® and its associated trade names across all EU member states.[45]
• 2025 (Projected): The drug continues to see development in its delivery systems, with recent FDA approvals for new ready-to-use formulations, such as B. Braun's DUPLEX® Drug Delivery System, aimed at improving convenience and safety in clinical practice.[67]

Concluding Remarks and Expert Synthesis

Piperacillin/tazobactam stands as a quintessential "workhorse" antibiotic in the modern hospital environment. Its enduring clinical importance stems from a powerful combination of attributes: an exceptionally broad spectrum of activity covering Gram-positive, Gram-negative, and anaerobic pathogens; potent anti-pseudomonal activity; and the restoration of efficacy against many β-lactamase-producing organisms. This profile makes it an invaluable agent for the initial empiric treatment of a wide range of severe and polymicrobial infections, from nosocomial pneumonia to complicated intra-abdominal sepsis.[6]

However, its widespread use and broad activity also necessitate a sophisticated understanding of its limitations and risks. The utility of piperacillin/tazobactam is constrained by the emergence of inhibitor-resistant β-lactamases, particularly AmpC enzymes and carbapenemases, which can mediate clinical failure. The debate over its role in treating ESBL-producing organisms highlights the need for a nuanced, evidence-based approach that considers infection severity and site, moving beyond a simplistic interpretation of susceptibility reports. Furthermore, the safety profile, while generally favorable, is punctuated by the risk of rare but severe immune-mediated reactions and dose-dependent toxicities, particularly neurotoxicity, which are amplified in the setting of renal impairment.

The future of this vital antimicrobial agent depends on robust antimicrobial stewardship. To preserve its efficacy for future generations, the use of piperacillin/tazobactam must be guided by several key principles. First, it should be reserved for appropriate indications, avoiding its use for infections where narrower-spectrum agents would suffice. Second, dosing strategies should be optimized based on pharmacodynamic principles—employing extended infusions where clinically appropriate to maximize the probability of therapeutic success and potentially suppress the emergence of resistance. Finally, vigilant monitoring for adverse effects and meticulous dose adjustment, particularly based on renal function, are paramount to ensuring patient safety. By adhering to these principles, the medical community can continue to leverage the immense therapeutic benefit of piperacillin/tazobactam while mitigating its risks and safeguarding its role as a cornerstone of anti-infective therapy.

Works cited

1. Piperacillin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB00319
2. Piperacillin-susceptibility testing-TOKU-E, accessed August 8, 2025, https://toku-e.com/piperacillin/
3. piperacillin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 8, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10921
4. Piperacillin - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Piperacillin
5. Piperacillin and Tazobactam Injection: MedlinePlus Drug Information, accessed August 8, 2025, https://medlineplus.gov/druginfo/meds/a694003.html
6. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/10353303/
7. piperacillin/tazobactam (Zosyn): Uses, Side Effects & Dosage - MedicineNet, accessed August 8, 2025, https://www.medicinenet.com/piperacillintazobactam_sodium-injection/article.htm
8. TAZOCIN* Piperacillin Sodium/Tazobactam Sodium NAME OF THE MEDICINE TAZOCIN* QUALITATIVE AND QUANTITATIVE COMPOSITION Piperacill, accessed August 8, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=13994
9. Piperacillin/Tazobactam: Mechanism of Action, Side Effects and Dosage, accessed August 8, 2025, https://www.urology-textbook.com/piperacillin-tazobactam.html
10. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. - DrugBank, accessed August 8, 2025, https://go.drugbank.com/articles/A179266
11. Piperacillin sodium - Sorachim SA, accessed August 8, 2025, https://sorachim.com/product/piperacillin-sodium/
12. Piperacillin | 61477-96-1 - ChemicalBook, accessed August 8, 2025, https://amp.chemicalbook.com/ChemicalProductProperty_EN_CB0181853.htm
13. Piperacillin monohydrate | C23H29N5O8S | CID 73246 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Piperacillin-hydrate
14. Piperacillin Monohydrate - CAS - 66258-76-2 | Axios Research, accessed August 8, 2025, https://www.axios-research.com/products/piperacillin-monohydrate
15. Piperacillin | CAS 61477-96-1 | SCBT - Santa Cruz Biotechnology, accessed August 8, 2025, https://www.scbt.com/p/piperacillin-61477-96-1
16. Piperacillin | C23H27N5O7S | CID 43672 - PubChem, accessed August 8, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/43672
17. [Piperacillin (350 mg)] - CAS [66258-76-2] - USP Store, accessed August 8, 2025, https://store.usp.org/product/1541500
18. CHEBI:8232 - piperacillin - EMBL-EBI, accessed August 8, 2025, https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:8232
19. PIPERACILLIN | 66258-76-2 - ChemicalBook, accessed August 8, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB9354306.htm
20. piperacillin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 8, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=10921
21. What is the mechanism of Piperacillin Sodium? - Patsnap Synapse, accessed August 8, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-piperacillin-sodium
22. ZOSYN® (Piperacillin and Tazobactam for Injection, USP) - Pfizer, accessed August 8, 2025, https://labeling.pfizer.com/showlabeling.aspx?id=502
23. Tazobactam: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/drugs/DB01606
24. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/17547502/
25. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 8, 2025, https://journals.asm.org/doi/10.1128/aac.01906-18
26. ZOSYN (piperacillin and tazobactam) for injection - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/Label/2017/050684s88s89s90_050750s37s38s39lbl.pdf
27. THE NEBRASKA MEDICAL CENTER SUPPORTING EVIDENCE FOR EXTENDED-INFUSION PIPERACILLIN/TAZOBACTAM DOSING SUBSTITUTION BACKGROUND:, accessed August 8, 2025, https://www.unmc.edu/intmed/_documents/id/asp/dose-pip-tazoei_protocol_detail-final.pdf
28. Piperacillin/tazobactam (Zosyn) - Infectious Diseases Management Program at UCSF, accessed August 8, 2025, https://idmp.ucsf.edu/content/piperacillintazobactam-zosyn
29. Piperacillin/Tazobactam Monograph for Professionals - Drugs.com, accessed August 8, 2025, https://www.drugs.com/monograph/piperacillin-tazobactam.html
30. Piperacillin/Tazobactam 4g/0.5g Powder for Solution for Infusion - Summary of Product Characteristics (SmPC) - (emc) | 6526, accessed August 8, 2025, https://www.medicines.org.uk/emc/product/6526/smpc
31. Clinical Pharmacology of Piperacillin/Tazobactam - Respub Journals, accessed August 8, 2025, https://respubjournals.com/clinical-biomedical-investigation/Clinical-Pharmacology-of-Piperacillin-Tazobactam.php
32. Piperacillin and Tazobactam for Injection - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/065386lbl.pdf
33. Population Pharmacokinetics of Piperacillin/Tazobactam across the Adult Lifespan - PMC, accessed August 8, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9969806/
34. Clinical pharmacology of piperacillin-tazobactam combination in infants and children, accessed August 8, 2025, https://www.oatext.com/clinical-pharmacology-of-piperacillin-tazobactam-combination-in-infants-and-children.php
35. Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions - PubMed, accessed August 8, 2025, https://pubmed.ncbi.nlm.nih.gov/6220262/
36. Piperacillin - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 8, 2025, https://www.pediatriconcall.com/drugs/piperacillin/878
37. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 8, 2025, https://journals.asm.org/doi/10.1128/aac.02747-15
38. Point-Counterpoint: Piperacillin-Tazobactam Should Be Used To Treat Infections with Extended-Spectrum-Beta-Lactamase-Positive Organisms | Journal of Clinical Microbiology, accessed August 8, 2025, https://journals.asm.org/doi/10.1128/jcm.01917-17
39. Piperacillin and Tazobactam for injection, for intravenous use - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050684s105lbl.pdf
40. A Homecoming — ZOSYN (piperacillin and tazobactam) Injection, accessed August 8, 2025, https://ushospitalproducts.baxter.com/zosyn-premix-for-injection
41. Piperacillin and Tazobactam: Package Insert / Prescribing Info - Drugs.com, accessed August 8, 2025, https://www.drugs.com/pro/piperacillin-and-tazobactam.html
42. PIPERACILLIN/ TAZOBACTAM TAZOCIN® 2 g/250 mg - Pfizer, accessed August 8, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12877
43. Tazocin - CHMP Opinion Art 30 - European Medicines Agency, accessed August 8, 2025, https://www.ema.europa.eu/en/documents/referral/tazocin-article-30-referral-annex-ii_en.pdf
44. Public Assessment Reports of the Medicines Evaluation Board in the Netherlands Piperacilline/Tazobactam 4 g/500 mg - CBG-Meb, accessed August 8, 2025, https://db.cbg-meb.nl/pars/h34088.pdf
45. Tazocin - referral | European Medicines Agency (EMA), accessed August 8, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/tazocin
46. Piperacillin Tazocilline Concentrations (Cmin) Completed Phase 4 Trials for Piperacillin (DB00319) | DrugBank Online, accessed August 8, 2025, https://go.drugbank.com/indications/DBCOND0040871/clinical_trials/DB00319?phase=4&status=completed
47. Piperacillin and tazobactam (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 8, 2025, https://www.mayoclinic.org/drugs-supplements/piperacillin-and-tazobactam-intravenous-route/description/drg-20072716
48. Piperacillin/Tazobactam (Zosyn): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 8, 2025, https://www.webmd.com/drugs/2/drug-16577/zosyn-intravenous/details
49. Piperacillin and tazobactam Uses, Side Effects & Warnings - Drugs.com, accessed August 8, 2025, https://www.drugs.com/mtm/piperacillin-and-tazobactam.html
50. Piperacillin-Tazobactam - LiverTox - NCBI Bookshelf, accessed August 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548825/
51. PIPERACILLIN AND TAZOBACTAM injection, powder, lyophilized, for solution - DailyMed, accessed August 8, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1cb1314-d3e0-4b44-a1df-de14c32e8cc6
52. piperacillin sodium,tazobactam sodium injection, powder, for solution - DailyMed, accessed August 8, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fc4d1e35-23eb-4654-8691-ae5bfd50a48a
53. Is the use of piperacillin/tazobactam associated with risk of acute kidney injury? | Drug Information Group | University of Illinois Chicago, accessed August 8, 2025, https://dig.pharmacy.uic.edu/faqs/2023-2/december-2023-faqs/is-the-use-of-piperacillin-tazobactam-associated-with-risk-of-acute-kidney-injury/
54. PipTaz-AFT Piperacillin 4 g and Tazobactam 500 mg, powder for injection - NEW ZEALAND DATA SHEET, accessed August 8, 2025, https://www.medsafe.govt.nz/profs/datasheet/p/PiptazAFTinj.pdf
55. Piperacillin/tazobactam - Wikipedia, accessed August 8, 2025, https://en.wikipedia.org/wiki/Piperacillin/tazobactam
56. Piperacillin - brand name list from Drugs.com, accessed August 8, 2025, https://www.drugs.com/ingredient/piperacillin.html
57. ffflJ) - Regulations.gov, accessed August 8, 2025, https://downloads.regulations.gov/FDA-2006-P-0019-0013/attachment_1.pdf
58. Label: PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE injection, solution - DailyMed, accessed August 8, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a63ca653-27d4-45fe-a744-77e0efe45220
59. Zosyn, (piperacillin-tazobactam) dosing, indications, interactions, adverse effects, and more, accessed August 8, 2025, https://reference.medscape.com/drug/zosyn-piperacillin-tazobactam-342485
60. What is the renal dosing for Zosyn (piperacillin/tazobactam) in patients with Impaired renal function? - Dr.Oracle AI, accessed August 8, 2025, https://www.droracle.ai/articles/61165/zosyn-renal-dosing-
61. Does Tazocin (piperacillin/tazobactam) require dosage adjustment in patients with Impaired renal function, as indicated by Glomerular Filtration Rate (GFR)? - Dr.Oracle, accessed August 8, 2025, https://www.droracle.ai/articles/45282/does-tazocin-piperacillintazobactam-require-dosage-adjustment-in-patients-with-impaired-renal-function-as-indicated-by-glomerular-filtration-rate-gfr
62. Piperacillin - LiverTox - NCBI Bookshelf, accessed August 8, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548463/
63. Generic Zosyn Availability - Drugs.com, accessed August 8, 2025, https://www.drugs.com/availability/generic-zosyn.html
64. PIPERACILLIN AND TAZOBACTAM injection, powder, lyophilized, for solution - DailyMed, accessed August 8, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8208ea-a632-4291-a90b-2eba9a33bb40
65. Zosyn: Side Effects, Dosage & Uses - Drugs.com, accessed August 8, 2025, https://www.drugs.com/zosyn.html
66. Drug Approval Package: Zosyn (Piperacillin & Tazobactam) NDA #050684s045 & 050750s012 - accessdata.fda.gov, accessed August 8, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/050684_S045_050750_s012_ZosynTOC.cfm
67. B. Braun Medical Inc. Announces US FDA Approval of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection in the DUPLEX® Drug Delivery System, accessed August 8, 2025, https://www.bbraunusa.com/en/about-us/media/company-news/2025/b--braun-medical-inc--announces-us-fda-approval-of-piperacillin-.html
68. B. Braun Medical Inc. Announces US FDA Approval of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection in the DUPLEX® Drug Delivery System - PR Newswire, accessed August 8, 2025, https://www.prnewswire.com/news-releases/b-braun-medical-inc-announces-us-fda-approval-of-piperacillin-and-tazobactam-for-injection-and-sodium-chloride-injection-in-the-duplex-drug-delivery-system-302423758.html